Registro de linfomas cutáneos primarios de la AEDV: primer año de funcionamiento

Peñate, Yeray; Servitje, Octavio; Machan, Salma; Fernández-de-Misa, Ricardo; Estrach, M.T.; Acebo, Elvira; Mitxelena, J.; Ramón, M.; Flórez, Ángeles; Blanes, Mar; Morillo, Mercedes; Medina, Susana; Bassas, J.; Zayas, Ana; Espinosa, Patricia; Pérez, Amparo Sancho; Gónzalez-Romero, N.; Dominguez, J.D.; Muniesa, Cristina; Robles, J. Lopez; Combalía, Andrea; Yanguas, I.; Suh, H.; Polo‐Rodríguez, I.; Bielsa, Isabel; Mateu, A.; Ferrer, Berta; Descalzo, M.Á.; García‐Doval, I.; Ortiz‐Romero, Pablo L.

doi:10.1016/j.ad.2018.03.006

Cited by 13 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9,33,34 Further studies should explore the potential impact in terms of productivity loss and health-related quality of life burden associated to the available treatments for the management of MF-CTCL. Treatment alternatives identified in this study are congruent with clinical data and treatment information on MF patients reported by AEDV's primary cutaneous lymphomas patient registry, 20 and also concur with the treatments recommended for early-stage MF management in the main clinical practice guidelines. 11,[30][31][32] Additionally, the therapeutic options assessed in this study are consistent with the first results shown by the AEDV's primary cutaneous lymphomas.…”

Section: Discussionsupporting

confidence: 82%

“…With regard to the systemic treatments assessed in this analysis, the use of systemic retinoids and IFNα was described by 6.9% and 12.1%, respectively, of MF patients recorded by the AEDV. 20 This is aligned with the indications from the expert panel consulted during this study, in which the use of combined therapies including systemic treatments for patients with early-stage MF is usually suggested for those non-eligible patients or those with a poor response to SDTs.…”

Section: Discussionmentioning

confidence: 56%

“…For this reason, having financial studies available is essential in order to include opportunity cost and cost-benefit elements among the arguments for assessing these treatments. Consequently, and taking advantage of the recently generated evidence from the AEDV registry of primary cutaneous lymphomas patients, 18,20 we would strongly encourage adding evidence related to healthcare resources use in prospective or retrospective studies already developed in our setting. This would not only allow us to corroborate the results of the current study, but also to promote the development of further pharmacoeconomic evidence regarding CTCLs.…”

Section: Discussionmentioning

confidence: 99%

“…Among the 348 recorded MF patients, the most common diagnosis was classical MF (77.3%), most of them (83.6%) presented early stages of the disease (IA-IIA). 20 In most cases, MF initially presents as an indolent condition with slow progression that tends to start with a patch phase, progressing in some patients to infiltrated plaques and finally evolving into a tumoral phase. 1,[21][22][23] The prognosis depends on the disease stage as determined by the International Society for Cutaneous Lymphomas (ISCL) and the European Organization for Research and Treatment of Cancer (EORTC).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Cost of early-stage mycosis fungoides treatments in Spain

Ortiz‐Romero

Servitje

Estrach³

et al. 2018

European Journal of Cancer

View full text Add to dashboard Cite

Aim: To identify the most common therapeutic options for the treatment of early-stage mycosis fungoides in Spain, quantify their associated healthcare resource use and costs. Methods: After reviewing the literature, a panel of 6 Spanish clinical dermatologists validated the treatments and healthcare resource use through a structured questionnaire. Individual responses were collected, analyzed and presented into a face-to-face meeting in order to reach a consensus. Cost categories considered were: drug acquisition and administration, photo/radiotherapy session and maintenance, clinical follow-up visits and laboratory tests. Costs were expressed in euros from 2018. The Spanish National Health System perspective was considered, taking into account direct health costs and time horizons of 1, 3 and 6 months. Results: Costs for the skin-directed treatments (SDT) assessed at 1, 3 and 6 months, were: Topical carmustine [€6,593.36, €19,780.09 and €27,592.78]; Phototherapy with psoralens and ultraviolet A light (PUVA) [€1,098.68, €2,999.99 and €3,187.60]; Narrow-band ultraviolet B phototherapy [€1,657.47, €4,842.10 and €4,842.10]; Total skin electron beam therapy (TSEBT) [€6,796.45, €7,913.34 and €7,913.34]. Cost for topical corticosteroids, being considered an adjuvant option, were €17.16, €51.49 and €102.97. Costs for the assessed systemic treatments alone or in combination with SDT at 1, 3 and 6 months, were: Systemic retinoids [€2,026.03, €5,206.63 and €7,426.42]; Systemic retinoids + PUVA phototherapy [€3,066.50, €8,271.26 and €10,046.58]; Interferon alfa + PUVA phototherapy [€1,541.09, €5,167.57 and €6,404.55].Conclusion: According to the Spanish clinical practice, phototherapies in monotherapy were the treatments with the lowest associated costs regardless of the time horizon considered. TSEBT turned out as the treatment with the highest associated costs when considering 1 month. However, while considering 3 and 6 months the treatment with the highest associated costs was topical carmustine. The results of this analysis may provide critical information to measure the disease burden, to detect unmet medical needs and to advocate towards better treatments for this rare disease. ClinicoEconomics and Outcomes Research Dovepressopen access to scientific and medical research Open Access Full Text Article submit your manuscript | www.dovepress.com ClinicoEconomics and Outcomes Research 2020:12 91-105

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionmentioning

confidence: 56%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Cost of early-stage mycosis fungoides treatments in Spain

Ortiz‐Romero

Servitje

Estrach³

et al. 2018

European Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…CTCLs are rare diseases with an annual incidence of around seven cases per million population [1]. The most common CTCLs are mycosis fungoides (MF) and Sézary syndrome (SS), which account for around 50% of all primary CTCLs [2,3]. This review focuses on MF/SS.…”

Section: Cutaneous T-cell Lymphoma: Description Of the Main Entitiesmentioning

confidence: 99%

Mycosis Fungoides and Sézary Syndrome: An Integrative Review of the Pathophysiology, Molecular Drivers, and Targeted Therapy

García-Díaz

Piris

Ortiz‐Romero

et al. 2021

Cancers

View full text Add to dashboard Cite

Primary cutaneous T-cell lymphomas (CTCLs) constitute a heterogeneous group of diseases that affect the skin. Mycosis fungoides (MF) and Sézary syndrome (SS) account for the majority of these lesions and have recently been the focus of extensive translational research. This review describes and discusses the main pathobiological manifestations of MF/SS, the molecular and clinical features currently used for diagnosis and staging, and the different therapies already approved or under development. Furthermore, we highlight and discuss the main findings illuminating key molecular mechanisms that can act as drivers for the development and progression of MF/SS. These seem to make up an orchestrated constellation of genomic and environmental alterations generated around deregulated T-cell receptor (TCR)/phospholipase C, gamma 1, (PLCG1) and Janus kinase/ signal transducer and activator of transcription (JAK/STAT) activities that do indeed provide us with novel opportunities for diagnosis and therapy.

show abstract

EORTC‐QLQ‐C30 and SKINDEX‐29 measurement of health‐related quality of life in patients with mycosis fungoides and Sézary syndrome: Real‐world data in Spanish patients (MICADOS Study)

Matilla

Gomis

Vallverdú

et al. 2022

JEADV Clinical Practice

View full text Add to dashboard Cite

Background Few studies have explored the impact of cutaneous T‐cell lymphoma (CTCL) on health‐related quality of life (HRQoL) and compared it to other patients with cancer. Objectives The primary objective of the study was to assess the QoL of patients diagnosed with the mycosis fungoides (MF) and Sézary syndrome (SS) types of CTCL in Spain. Methods A cross‐sectional observational study was completed recruiting adult patients with MF and SS, exploring the European Organisation for Research and Treatment of Cancer‐Core Quality of Life Questionnaire, version 3 (EORTC‐QLQ‐C30v3) and Skindex‐29 HRQoL and itching intensity. Results A total of 141 patients [81 males (57.4%) and mean age of 63.6 years (95% CI: 61.4–65.7)], were included. EORTC‐QLQ‐C30 global health status showed worse scores in CTCL patients compared to healthy population (p < 0.05) and did not differ from other patients with cancer. The physical and role functioning of CTCL patients were better than other patients with cancer (p < 0.05) but worse than healthy population (p < 0.05). The social functioning was similar to other patients with cancer but worse than healthy (p < 0.05). In the global health status, better scores were observed with aging (p = 0.023) and worse scores in patients with Eastern Cooperative Oncology Group (ECOG)‐1 versus ECOG‐0 (p = 0.01). The Skindex‐29 global score was 28.5 (95% CI: 24.8–32.3), being worst at higher clinical stage (p < 0.05) and at higher pruritus intensity (p < 0.001) and better for older patients (p < 0.001). More itching was related to female sex (p = 0.016), younger patients (p = 0.035), higher ECOG (p < 0.05) and higher m‐SWAT scores (p = 0.006). Conclusions These results allow mapping HRQoL affectation in CTCL patients. Global health status in MF/SS was like other patients with cancer and worse than the age‐matched healthy population. The highest impact in Skindex‐29 and EORTC‐QLQ‐C30 was associated with young age, ECOG, pruritus and disease stage.

show abstract

Registro de linfomas cutáneos primarios de la AEDV: primer año de funcionamiento

Cited by 13 publications

References 19 publications

Cost of early-stage mycosis fungoides treatments in Spain

Cost of early-stage mycosis fungoides treatments in Spain

Mycosis Fungoides and Sézary Syndrome: An Integrative Review of the Pathophysiology, Molecular Drivers, and Targeted Therapy

EORTC‐QLQ‐C30 and SKINDEX‐29 measurement of health‐related quality of life in patients with mycosis fungoides and Sézary syndrome: Real‐world data in Spanish patients (MICADOS Study)

Contact Info

Product

Resources

About